免疫检查点TIGIT/CD155对原发性肝癌免疫微环境的调控作用及应用展望

姚帆; 殷欣

doi:10.3969/j.issn.1001-5256.2022.11.039

免疫检查点TIGIT/CD155对原发性肝癌免疫微环境的调控作用及应用展望

DOI: 10.3969/j.issn.1001-5256.2022.11.039

姚帆,
殷欣^, ,

复旦大学附属中山医院肝肿瘤内科, 上海 200030

基金项目:

国家自然科学基金 (81972889)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：殷欣对文章的思路有关键贡献并参与修改文章关键内容；姚帆参与收集关键参考文献以及撰写文章。

详细信息

通信作者:
殷欣, yin.xin@zs-hospital.sh.cn

计量
- 文章访问数: 698
- HTML全文浏览量: 138
- PDF下载量: 85
- 被引次数: 0
出版历程
- 收稿日期: 2022-04-01
- 录用日期: 2022-05-09
- 出版日期: 2022-11-20

Regulatory effect of immune checkpoint TIGIT/CD155 on the immune microenvironment of primary liver cancer and its application prospects

Fan YAO,
Xin YIN^{,
,}

Department of Liver Oncology, Zhongshan Hospital, Fudan University, Shanghai 200030, China

Research funding:

National Natural Science Foundation of China (81972889)

More Information

Corresponding author: YIN Xin, yin.xin@zs-hospital.sh.cn(ORCID: 0000-0002-9892-7845)

摘要

摘要: 随着免疫检查点抑制剂在各种实体瘤中得到了应用，耐药性和疗效不佳等问题随之而来，所以为了更好地改善患者的预后，探索更佳的免疫治疗方案刻不容缓。本文介绍了一种新兴的免疫检查点TIGIT及其高亲和力配体CD155，总结了TIGIT/CD155通路对肝癌免疫微环境的调控作用，并归纳了针对TIGIT的抑制剂在肝癌免疫治疗中的应用。认为TIGIT/CD155可以通过免疫细胞和基质细胞等改变肝癌的免疫微环境，从而造成免疫逃逸使病情恶化。分析表明，针对TIGIT的靶向治疗会成为将来肝癌治疗发展的新方向，并在免疫联合治疗中发挥重要作用。
- 肝肿瘤 /
- 免疫抑制剂 /
- 肿瘤微环境
Abstract: With the application of immune checkpoint inhibitors in various solid tumors, problems such as drug resistance and poor response gradually occur, and therefore, in order to better improve the prognosis of patients, it is urgent to explore better immunotherapy regimens. This article introduces an emerging immune checkpoint TIGIT and its high-affinity ligand CD155 and summarizes the regulatory effect of the TIGIT/CD155 pathway on the immune microenvironment of liver cancer and the application of inhibitors targeting TIGIT in immunotherapy for liver cancer. It is believed that TIGIT/CD155 can change the immune microenvironment of liver cancer through immune cells and stromal cells, thereby causing immune escape and worsening of disease conditions. The analysis shows that the targeted therapy for TIGIT will become a new direction for the development of liver cancer therapy and play an important role in combined immunotherapy.
- Liver Neoplasms /
- Immunosuppressive Agents /
- Tumor Microenvironment

HTML全文

图 1 TIGIT/CD155通路对肝癌免疫微环境的调控作用

Figure 1. Regulation of TIGIT/CD155 pathway on immune microenvironment of hepatocellular carcinoma

下载: 全尺寸图片幻灯片

表 1 TIGIT免疫检查点抑制剂在实体瘤免疫治疗中的应用

Table 1. Application of TIGIT immune checkpoint inhibitors in immunotherapy of solid tumor

TIGIT抑制剂	试验号	研究年份	研究疾病	试验内容	试验阶段	试验方式
BGB-A1217	NCT04948697	2021年	晚期HCC	与贝伐珠单抗(BAT1706)或替雷利珠单抗(BGB-A317)联合治疗	Ⅱ期	对照试验
AB154	NCT03628677	2018年	晚期恶性实体肿瘤	单药治疗或与塞帕利单抗(AB122)联合治疗	Ⅰ期	对照试验
IBI-939	NCT04353830	2020年	晚期恶性肿瘤	单药治疗或与信迪利单抗联合治疗	Ⅰ期	对照试验
M-6223	NCT04457778	2020年	转移性或局部晚期不可切除实体肿瘤	单药治疗或与M7824(PD-1/TGFβ双靶向药物)联合治疗	Ⅰ期	对照试验
AGEN1777	NCT05025085	2020年	晚期实体肿瘤	单药治疗或与一种PD-1抑制剂联合治疗	Ⅰ期	对照试验
IBI-321	NCT04911894 NCT04911881	2021年	晚期实体肿瘤	单药治疗	Ⅰ期	单臂试验
MK-7684	NCT05007106	2021年	包括HCC在内的8种晚期实体肿瘤	与PD-1抑制剂或分子靶向药物等联合治疗	Ⅱ期	对照试验
ASP8374	NCT03945253	2019年	晚期实体肿瘤	单药治疗	Ⅰ期	对照试验
BAT6005	NCT05116709	2021年	局部或转移性晚期实体肿瘤	单药治疗	Ⅰ期	单臂试验

下载: 导出CSV

参考文献(27)

[1]	BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
[2]	YUAN SX, ZHOU WP. Progress and hot spots of comprehensive treatment for primary liver cancer[J]. Chin J Dig Surg, 2021, 20(2): 163-170. DOI: 10.3760/cma.j.cn115610-20201211-00776. 袁声贤, 周伟平. 原发性肝癌综合治疗的进展和热点[J]. 中华消化外科杂志, 2021, 20(2): 163-170. DOI: 10.3760/cma.j.cn115610-20201211-00776.
[3]	WEI JY, SUN W, LIU XM, et al. Advances in targeted therapy and immunotherapy for hepatocelluar carcinoma[J]. J Clin Hepatol, 2020, 36(10): 2320-2324. DOI: 10.3969/j.issn.1001-5256.2020.10.035. 魏建莹, 孙巍, 刘晓民, 等. 肝细胞癌的靶向及免疫治疗进展[J]. 临床肝胆病杂志, 2020, 36(10): 2320-2324. DOI: 10.3969/j.issn.1001-5256.2020.10.035.
[4]	QIN XY, LIU YY, KANG Q. Prevention and therapeutic strategies and targeted immunotherapy for hepatocellular carcinoma recurrence and metastasis after liver transplantation[J]. Ogran Transplant, 2022, 13(2): 271-276. DOI: 10.3969/j.issn.1674-7445.2022.02.018. 秦小琰, 刘彦尧, 康权. 肝癌肝移植术后复发转移的防治策略和靶向免疫治疗[J]. 器官移植, 2022, 13(2): 271-276. DOI: 10.3969/j.issn.1674-7445.2022.02.018.
[5]	ZONGYI Y, XIAOWU L. Immunotherapy for hepatocellular carcinoma[J]. Cancer Lett, 2020, 470: 8-17. DOI: 10.1016/j.canlet.2019.12.002.
[6]	SADEGHI RAD H, MONKMAN J, WARKIANI ME, et al. Understanding the tumor microenvironment for effective immunotherapy[J]. Med Res Rev, 2021, 41(3): 1474-1498. DOI: 10.1002/med.21765.
[7]	GUAN QT, HAN MW, XI D. Research progress of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma[J]. J Inter Intens Med, 2021, 27(3): 187-192. DOI: 10.11768/nkjwzzzz20210303. 关倩婷, 韩美文, 习东. 免疫检查点抑制剂治疗肝细胞癌的研究进展[J]. 内科急危重症杂志, 2021, 27(3): 187-192. DOI: 10.11768/nkjwzzzz20210303.
[8]	YU X, HARDEN K, GONZALEZ LC, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells[J]. Nat Immunol, 2009, 10(1): 48-57. DOI: 10.1038/ni.1674.
[9]	DUAN X, LIU J, CUI J, et al. Expression of TIGIT/CD155 and correlations with clinical pathological features in human hepatocellular carcinoma[J]. Mol Med Rep, 2019, 20(4): 3773-3781. DOI: 10.3892/mmr.2019.10641.
[10]	LUPO KB, MATOSEVIC S. CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma[J]. J Hematol Oncol, 2020, 13(1): 76. DOI: 10.1186/s13045-020-00913-2.
[11]	ZHANG J, ZHU Y, WANG Q, et al. Poliovirus receptor CD155 is up-regulated in muscle-invasive bladder cancer and predicts poor prognosis[J]. Urol Oncol, 2020, 38(2): 41. DOI: 10.1016/j.urolonc.2019.07.006.
[12]	SUN H, HUANG Q, HUANG M, et al. Human CD96 correlates to natural killer cell exhaustion and predicts the prognosis of human hepatocellular carcinoma[J]. Hepatology, 2019, 70(1): 168-183. DOI: 10.1002/hep.30347.
[13]	DEUSS FA, WATSON GM, FU Z, et al. Structural basis for CD96 immune receptor recognition of nectin-like protein-5, CD155[J]. Structure, 2019, 27(2): 219-228. e3. DOI: 10.1016/j.str.2018.10.023.
[14]	ZHANG C, WANG Y, XUN X, et al. TIGIT can exert immunosuppressive effects on CD8⁺ T cells by the CD155/TIGIT signaling pathway for hepatocellular carcinoma in vitro[J]. J Immunother, 2020, 43(8): 236-243. DOI: 10.1097/CJI.0000000000000330.
[15]	LIU X, LI M, WANG X, et al. PD-1⁺ TIGIT⁺ CD8⁺ T cells are associated with pathogenesis and progression of patients with hepatitis B virus-related hepatocellular carcinoma[J]. Cancer Immunol Immunother, 2019, 68(12): 2041-2054. DOI: 10.1007/s00262-019-02426-5.
[16]	ZONG L, PENG H, SUN C, et al. Breakdown of adaptive immunotolerance induces hepatocellular carcinoma in HBsAg-tg mice[J]. Nat Commun, 2019, 10(1): 221. DOI: 10.1038/s41467-018-08096-8.
[17]	SHI H, CHI H. Metabolic control of treg cell stability, plasticity, and tissue-specific heterogeneity[J]. Front Immunol, 2019, 10: 2716. DOI: 10.3389/fimmu.2019.02716.
[18]	TREHANPATI N, VYAS AK. Immune regulation by T regulatory cells in hepatitis B virus-related inflammation and cancer[J]. Scand J Immunol, 2017, 85(3): 175-181. DOI: 10.1111/sji.12524.
[19]	JOLLER N, LOZANO E, BURKETT PR, et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses[J]. Immunity, 2014, 40(4): 569-581. DOI: 10.1016/j.immuni.2014.02.012.
[20]	SUN C, XU J, HUANG Q, et al. High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer[J]. Oncoimmunology, 2017, 6(1): e1264562. DOI: 10.1080/2162402X.2016.1264562.
[21]	YU L, LIU X, WANG X, et al. TIGIT⁺ TIM-3⁺ NK cells are correlated with NK cell exhaustion and disease progression in patients with hepatitis B virus-related hepatocellular carcinoma[J]. Oncoimmunology, 2021, 10(1): 1942673. DOI: 10.1080/2162402X.2021.1942673.
[22]	YIN Z, DONG C, JIANG K, et al. Heterogeneity of cancer-associated fibroblasts and roles in the progression, prognosis, and therapy of hepatocellular carcinoma[J]. J Hematol Oncol, 2019, 12(1): 101. DOI: 10.1186/s13045-019-0782-x.
[23]	INOUE T, ADACHI K, KAWANA K, et al. Cancer-associated fibroblast suppresses killing activity of natural killer cells through downregulation of poliovirus receptor (PVR/CD155), a ligand of activating NK receptor[J]. Int J Oncol, 2016, 49 (4) : 1297-1304. DOI: 10.3892/ijo.2016.3631.
[24]	HORVATH L, PIRCHER A. ASCO 2020 non-small lung cancer (NSCLC) personal highlights[J]. Memo, 2021, 14(1): 66-69. DOI: 10.1007/s12254-020-00673-2.
[25]	LI D. Research progress of immune checkpoint PD-1/PD-L1 inhibitor resistance mechanism and treatment strategy[J]. China & Foreign Medical Treatment, 2021, 40(17): 195-198. DOI: 10.16662/j.cnki.1674-0742.2021.17.195. 李典. 免疫检查点PD-1/PD-L1抑制剂耐药机制与治疗策略的研究进展[J]. 中外医疗, 2021, 40(17): 195-198. DOI: 10.16662/j.cnki.1674-0742.2021.17.195.
[26]	HUNG AL, MAXWELL R, THEODROS D, et al. TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM[J]. Oncoimmunology, 2018, 7(8): e1466769. DOI: 10.1080/2162402X.2018.1466769.
[27]	HAN HS, JEONG S, KIM H, et al. TOX-expressing terminally exhausted tumor-infiltrating CD8⁺ T cells are reinvigorated by co-blockade of PD-1 and TIGIT in bladder cancer[J]. Cancer Lett, 2021, 499: 137-147. DOI: 10.1016/j.canlet.2020.11.035.